Clinical trials
Pancreatic Ductal Adenocarcinoma clinical trials
Below are recruiting pancreatic ductal adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 228 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04990609RecruitingPhase 2
Study for pancreatic cancer using a biopsy-confirmed treatment approach
This Phase 2 trial is for people with pancreatic ductal adenocarcinoma (a type of pancreatic cancer) confirmed by biopsy. It tests a new treatment strategy after the cancer is diagnosed and considers people who haven’t had certain chemotherapy yet.
Houston, TexasAges 18 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Birmingham, AlabamaAges 1–30 - NCT04657068RecruitingPhase 1/Phase 2
Study of ART0380 for advanced solid tumors
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
Birmingham, AlabamaAges 18 years+ - NCT07594964RecruitingPhase 1
Safety Study of XH001 Injection for High-Risk Recurrent Solid Tumors
This early-stage trial tests a new injection called XH001 as an additional treatment after surgery for patients with high-risk cancers that have come back. The goal is to check if it's safe and whether it helps prevent the cancer from returning again.
BeijingAges 18–70 - NCT07589205RecruitingPhase 1
Testing IBI3028 for Advanced Solid Tumors
This early-stage trial tests a new drug called IBI3028 in people with advanced cancers that cannot be removed by surgery or have spread. The study aims to find the right dose and understand how the drug works in your body.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07587866Recruiting
Panuri Test for Suspected Pancreatic Cancer
This study tests a new diagnostic tool called Panuri to help detect pancreatic cancer in adults who have symptoms suggesting the disease. The test may help doctors identify pancreatic cancer earlier and more accurately.
BékéscsabaAges 18 years+ - NCT07640295RecruitingPhase 1/Phase 2
New drug plus chemo for advanced pancreatic cancer with KRAS mutation
This study tests a new drug combined with chemotherapy for people with pancreatic cancer that has spread and has a KRAS gene mutation. It may help shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07812805RecruitingPhase 1
New targeted treatment with imaging for advanced solid tumors
This trial tests a new experimental treatment (SKL35501) that uses a special imaging agent (SKL35502) to find and target a marker called NTSR1 found on some advanced cancers. The goal is to see if this treatment is safe and can help people whose cancer has stopped responding to standard treatments.
Glen Burnie, MarylandAges 18 years+ - NCT07702292RecruitingPhase 2
68Ga-BED003 PET scan for certain cancers
This trial tests a new PET imaging agent that targets a protein called FAP, which appears in many solid tumors. The goal is to see if this scan can better find and measure cancer in the body.
Bergamo, LombardyAges 18–79 - NCT07629960RecruitingPhase 1/Phase 2
New KRAS-Targeting Drug for Advanced Solid Tumors
This early-stage trial tests BLU-924, a new drug designed to target cancer cells with specific KRAS mutations (a common genetic change in pancreatic, lung, and colon cancers). The study aims to find the right dose and see how well it works in patients whose cancers have progressed despite standard treatments.
Sarasota, FloridaAges 18 years+ - NCT07522073RecruitingPhase 3
Chemotherapy with or without KRAS inhibitor for pancreatic cancer
This study tests whether adding a new drug called INCB161734 to standard chemotherapy helps people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D mutation). You would be randomly assigned to receive either chemotherapy alone or chemotherapy plus the new drug.
Birmingham, AlabamaAges 18 years+ - NCT07769502RecruitingPhase 2
Treatment for advanced bile duct and pancreatic cancers
This trial is studying a new drug, telisotuzumab adizutecan, in combination with other treatments for advanced bile duct or pancreatic cancers. The goal is to see if the combination helps control the cancer. It's designed for people who are relatively active and can do their daily tasks.
Hattiesburg, MississippiAges 18 years+ - NCT07500259Recruiting
Personalized drug testing for GI tumors
This trial uses a lab test to see how your tumor responds to different drugs, helping doctors choose the best treatment for you. It is for people with pancreatic cancer (PDAC) who are having surgery or a biopsy.
Luxembourg, LuxembourgAges 18 years+ - NCT06828328RecruitingEarly Phase 1
Gene-edited TIL therapy for pancreatic cancer
This trial tests a new treatment called GC203 TIL, which uses your own immune cells (TILs) that have been gene-edited to fight pancreatic cancer. It is for people whose cancer has not responded to standard treatments and who are healthy enough to undergo this therapy.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT04099134Recruiting
Registry study for pancreatic ductal cancer before treatment
This is a “registry” study that collects health information from adults with pancreatic ductal adenocarcinoma before starting treatment. It may help researchers better understand the disease and how patients are managed in real life.
UlmAges 18 years+ - NCT07409272RecruitingPhase 3
Study of setidegrasib with chemo for pancreatic cancer
This trial tests a new drug called setidegrasib, given with two types of chemotherapy (mFOLFIRINOX or NALIRIFOX), for people whose pancreatic cancer has spread and has a specific genetic change called KRAS G12D. The goal is to see if adding setidegrasib helps control the cancer better than chemo alone.
Tucson, ArizonaAges 18 years+ - NCT06789679RecruitingPhase 2
Adding S-1 to standard chemo for advanced pancreatic cancer
This trial tests whether adding a third drug (S-1, a chemotherapy pill) to the standard two-drug IV chemo (albumin-bound paclitaxel and gemcitabine) can help people with advanced pancreatic cancer live longer. It's for those who haven't had treatment yet for their advanced cancer.
Beijing, Chaoyang DistrictAges 18 years+ - NCT05752812Recruiting
HELPP score study for pancreatic cancer outcomes
This study looks at a pretreatment score (called the HELPP score) to predict survival in people with localized pancreatic ductal adenocarcinoma. It may help doctors better estimate outcomes based on information gathered before treatment.
ViennaAges 18–99 - NCT06861452RecruitingPhase 1/Phase 2
Testing a new drug after chemo for advanced pancreatic cancer
This study tests an investigational drug (RR001) given after chemotherapy for people with locally advanced pancreatic cancer that hasn't spread. It aims to see if the new treatment is safe and may help shrink tumors that can be reached with a needle injection.
Modena, ItalyAges 18 years+ - NCT06966440Recruiting
MRD-Guided Chemotherapy After Pancreatic Cancer Surgery
This trial tests whether using a special blood test (MRD) to guide chemotherapy after pancreatic cancer surgery can improve outcomes. It is for people who have had their cancer completely removed and are ready for standard follow-up therapy.
ShanghaiAges 18–75 - NCT07700992Recruiting
A blood test to find pancreatic cancer early
This study uses stored blood samples from people at higher risk for pancreatic cancer (due to family history or certain pancreatic cysts) to see if a simple blood test can detect the disease early or help monitor it over time.
Milan, MIAges 18–99 - NCT07701486RecruitingPhase 1/Phase 2
Testing more frequent VCN-01 with standard chemo for new pancreatic cancer
This study tests a more frequent schedule of the experimental drug VCN-01 along with standard chemotherapy (nab-paclitaxel and gemcitabine) for people newly diagnosed with pancreatic cancer that has spread. The goal is to see if the virus-based therapy can help shrink tumors better.
Madrid, MadridAges 18 years+ - NCT05837767Recruiting
Radiation study for tumors that spread to soft tissue areas
This study looks at how a planned form of palliative radiation therapy treats certain solid cancers that have spread outside the brain to larger soft-tissue areas. It may help shrink tumors and relieve symptoms, but it also asks you to meet specific safety and treatment-timing rules.
Basking Ridge, New JerseyAges 18 years+ - NCT07532590Recruiting
Pancreas Plus: smartphone app for pancreatic cancer monitoring
This study tests a smartphone app designed to help people with pancreatic cancer track their health and receive educational information about their condition. The app asks simple questions regularly and provides supportive content to help you stay informed and connected to your care team.
Pavia, PaviaAges 18 years+
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pancreatic ductal adenocarcinoma?
- Yes. Clin2 currently lists 228 recruiting pancreatic ductal adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pancreatic ductal adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pancreatic ductal adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Metastatic Pancreatic Ductal Adenocarcinoma
- Locally Advanced Pancreatic Ductal Adenocarcinoma
- Borderline Resectable Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (mPDAC)
- Resectable Pancreatic Ductal Adenocarcinoma
- Advanced Pancreatic Ductal Adenocarcinoma
- Unresectable Pancreatic Ductal Adenocarcinoma
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.